. Author manuscript; available in PMC: 2016 Dec 16.

Published in final edited form as: Am J Obstet Gynecol. 2011 Jun 24;205(6):535.e1–535.e5. doi: 10.1016/j.ajog.2011.06.067

Table 4.

Average annual rates of gynecological conditions and procedures by treatment group in the NSABP STAR P-2 trial

Condition or Procedure	Number of Events		Rate per 1000			Risk Ratio (RR)^†	RR 95% Confidence Interval
Condition or Procedure	Tamoxifen	Raloxifene	Tamoxifen	Raloxifene	Difference^*	Risk Ratio (RR)^†	RR 95% Confidence Interval
Conditions
Leiomyomas	757	443	28.40	15.56	12.84	0.55	0.49 to 0.62
Ovarian cysts	236	147	8.32	5.01	3.31	0.60	0.49 to 0.74
Polyps	575	185	21.06	6.28	14.78	0.30	0.25 to 0.35
Endometriosis	190	64	6.60	2.14	4.46	0.32	0.24 to 0.43
Procedures
Curettage	673	218	24.30	7.32	16.98	0.30	0.26 to 0.35
Bilateral oophorectomy	371	192	12.80	6.46	6.34	0.50	0.42 to 0.60
Laparoscopy	14	4	0.46	0.13	0.33	0.28	0.07 to 0.90
Hysteroscopy	493	151	17.32	5.03	12.29	0.29	0.24 to 0.35

Rate in the tamoxifen group minus rate in the raloxifene group.

^†

Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.